[(3S,4S)-1-benzyl-4-(2-oxopiperidin-1-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester | 1000303-31-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(3S,4S)-1-benzyl-4-(2-oxopiperidin-1-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester
• 英文别名: tert-butyl (3S,4S)-1-Benzyl-4-(2-oxopiperidin-1-yl)pyrrolidin-3-ylcarbamate；tert-butyl N-[(3S,4S)-1-benzyl-4-(2-oxopiperidin-1-yl)pyrrolidin-3-yl]carbamate
• CAS: 1000303-31-0
• 化学式: C₂₁H₃₁N₃O₃
• 分子量: 373.495
• InChiKey: FNOOJHQGRQYPAA-ROUUACIJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [(3S,4S)-1-benzyl-4-(2-oxopiperidin-1-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 在 palladium 10% on activated carbon 氢气 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 80.0~90.0 ℃ 、1.0 MPa 条件下， 反应 144.0h， 生成 [(3S,4S)-1-(5-{(S)-1-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]ethoxy}pyrimidin-2-yl)-4-(2-oxopiperidin-1-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  [EN] CYCLOAMINO DERIVATIVES AS GPR119 AGONISTS
  [FR] DÉRIVÉS DE CYCLOAMINO COMME ANTAGONISTES DU GPR119

  摘要：

  公开号：

  WO2011147951A8
• 作为产物：
  描述：

  (3S,4S)-1-苄基吡咯烷-3,4-二醇 在 sodium azide 、 sodium hydride 、 1-丙基磷酸酐 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 [(3S,4S)-1-benzyl-4-(2-oxopiperidin-1-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes

  摘要：

  A 3-amino-4-substituted pyrrolidine series of dipeptidyl peptidase IV (DPP-4) inhibitors was rapidly developed into a candidate series by identification of a polar valerolactam replacement for the lipophilic 2,4,5-trifluorophenyl pharmacophore. The addition of a gem-difluoro substituent to the lactam improved overall DPP-4 inhibition and an efficient asymmetric route to 3,4-diaminopyrrolidines was developed. Advanced profiling of a subset of analogs identified 5o with an acceptable human DPP-4 inhibition profile based on a rat PK/PD model and a projected human dose that was suitable for clinical development. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.055

文献信息

• Substituted 3-Amino-Pyrrolidino-4-Lactams
  申请人：Piotrowski David W.

  公开号：US20070299076A1

  公开（公告）日：2007-12-27

  The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R 1 , n and R 2 are as described herein; compositions thereof; and uses thereof.

  这项发明提供了式（1）的化合物，以及其药用可接受的盐，其中R1、n和R2如本文所述；以及它们的组合物；以及它们的用途。
• [EN] COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：PROSIDION LTD

  公开号：WO2010103335A1

  公开（公告）日：2010-09-16

  The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

  本发明涉及具有 GPR119 激动剂活性的治疗化合物，适用于治疗代谢性疾病，包括Ⅱ型糖尿病。
• Compounds for the Treatment of Metabolic Disorders
  申请人：Barba Oscar

  公开号：US20120040953A1

  公开（公告）日：2012-02-16

  The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

  本发明涉及治疗化合物，其具有作为GPR119激动剂的活性，并且适用于治疗代谢性疾病，包括2型糖尿病。
• Substituted 3-amino-pyrrolidino-4-lactams
  申请人：Pfizer, Inc.

  公开号：US07485641B2

  公开（公告）日：2009-02-03

  The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R1, n and R2 are as described herein; compositions thereof; and uses thereof.

  本发明提供了式(1)的化合物及其药学上可接受的盐，其中R1、n和R2如本文所述；它们的组成；以及它们的用途。
• 1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes
  作者：Kim M. Andrews、David A. Beebe、John W. Benbow、David A. Boyer、Shawn D. Doran、Yu Hui、Shenping Liu、R. Kirk McPherson、Constantin Neagu、Janice C. Parker、David W. Piotrowski、Steven R. Schneider、Judith L. Treadway、Maria A. VanVolkenberg、William J. Zembrowski

  DOI：10.1016/j.bmcl.2011.01.055

  日期：2011.3

  A 3-amino-4-substituted pyrrolidine series of dipeptidyl peptidase IV (DPP-4) inhibitors was rapidly developed into a candidate series by identification of a polar valerolactam replacement for the lipophilic 2,4,5-trifluorophenyl pharmacophore. The addition of a gem-difluoro substituent to the lactam improved overall DPP-4 inhibition and an efficient asymmetric route to 3,4-diaminopyrrolidines was developed. Advanced profiling of a subset of analogs identified 5o with an acceptable human DPP-4 inhibition profile based on a rat PK/PD model and a projected human dose that was suitable for clinical development. (C) 2011 Elsevier Ltd. All rights reserved.